An open-label clinical trial of oral transmucosal haloperidol and oral transmucosal olanzapine in the treatment of terminal delirium at home

被引:1
|
作者
Xiao-Juan Lyu [1 ]
Kan, Adrian David [1 ]
Poh-Heng Chong [1 ]
Lin, Keegan [1 ]
Yung-Hua Koh [2 ]
Zhi-Zheng Yeo [1 ]
机构
[1] HCA Hosp, Singapore, Singapore
[2] IPOS Int, Singapore, Singapore
关键词
Haloperidol; Olanzapine; Terminal delirium; Home hospice; Palliative care; End of life; MANAGEMENT; CANCER; SEDATION; SCALE; END;
D O I
10.1186/s13063-022-06238-4
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: The phenomenon of restlessness, agitation, or cognitive disturbances experienced by dying patients is well-known in palliative care; more than half of these patients will experience delirium symptoms at end-of-life. When not identified early and effectively managed, delirium symptoms could lead to caregiver and patient distress and harm. Methods: Eighty patients with a prognosis of 7 days or less will be recruited for an open-label randomised control trial. The two arms compare oral-transmucosal haloperidol 2.5 mg vs olanzapine 5 mg over 72 h. The severity of agitation, delirium and toxicities of treatments will be compared at the 24th, 48th and 72nd hour after drug administration. Discussion: This trial is the first to compare anti-psychotics in the management of delirium at the dying stage in the home hospice setting using the oral transmucosal route. Ethical considerations, as well as recruitment procedures, are discussed.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] An open-label clinical trial of oral transmucosal haloperidol and oral transmucosal olanzapine in the treatment of terminal delirium at home
    Xiao-Juan Lyu
    Adrian David Kan
    Poh-Heng Chong
    Keegan Lin
    Yung-Hua Koh
    Zhi-Zheng Yeo
    Trials, 23
  • [2] A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial
    Mercadante, S.
    Radbruch, L.
    Davies, A.
    Poulain, P.
    Sitte, T.
    Perkins, P.
    Colberg, T.
    Camba, M. A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (11) : 2805 - 2815
  • [3] AN OPEN LABEL STUDY OF ORAL TRANSMUCOSAL FENTANYL CITRATE (OTFC) FOR THE TREATMENT OF BREAKTHROUGH CANCER PAIN
    FINE, PG
    MARCUS, M
    DEBOER, AJ
    VANDEROORD, B
    PAIN, 1991, 45 (02) : 149 - 153
  • [4] A long-term, open label study of oral transmucosal fentanyl citrate in patients with cancer
    Charapata, S
    McCracken, M
    ANESTHESIOLOGY, 1997, 87 (03) : A827 - A827
  • [5] Olanzapine treatment in Tourette syndrome: An open-label trial
    Lin, JJ
    Chang, DC
    MOVEMENT DISORDERS, 2002, 17 : S339 - S339
  • [6] Efficacy and patient preference for intranasal fentanyl spray (INFS) versus oral transmucosal fentanyl citrate (OTFC) for breakthrough cancer pain - an open-label crossover trial
    Mercadante, S.
    Popper, L.
    EJC SUPPLEMENTS, 2009, 7 (02): : 254 - 254
  • [7] An open-label randomized trial of intramuscular olanzapine versus oral clonidine for symptomatic treatment of opioid withdrawal in the emergency department*
    Klein, Lauren R.
    Cole, Jon B.
    Driver, Brian E.
    Miner, James R.
    Laes, JoAn R.
    Fagerstrom, Erik
    Martel, Marc L.
    CLINICAL TOXICOLOGY, 2019, 57 (08) : 697 - 702
  • [8] A randomized, clinical trial of oral midazolam plus placebo versus oral midazolam plus oral transmucosal fentanyl for sedation during laceration repair
    Klein, EJ
    Diekema, DS
    Paris, CA
    Quan, L
    Cohen, M
    Seidel, KD
    PEDIATRICS, 2002, 109 (05) : 894 - 897
  • [9] Open-label trial of oral nalmefene therapy for the pruritus of cholestasis
    Bergasa, NV
    Schmitt, JM
    Talbot, TL
    Alling, DW
    Swain, MG
    Turner, ML
    Jenkins, JB
    Jones, EA
    HEPATOLOGY, 1998, 27 (03) : 679 - 684
  • [10] Comparison of Oral Azathioprine and Oral Mini Pulse Steroid in the Treatment of Vitiligo: An Open-Label Randomized Controlled Trial
    Jawade, Sugat
    Saoji, Vikrant
    Madke, Bhushan
    Singh, Adarshlata
    INDIAN JOURNAL OF DERMATOLOGY, 2023, 68 (06) : 591 - 597